Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 15 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

3 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

6(60.0%)

Phase 4

2(20.0%)

Phase 3

1(10.0%)

Phase 2

1(10.0%)

10Total

N/A(6)

Phase 4(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT06820281Phase 2Not Yet Recruiting

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

Role: lead

NCT03558867Not ApplicableCompleted

Personalised Medicine in Pre-diabetes and Early Type 2 Diabetes

Role: lead

NCT04511416Phase 3Active Not Recruiting

Preventing Cognitive Decline with Metformin

Role: lead

NCT03336931Active Not Recruiting

PRecISion Medicine for Children With Cancer

Role: collaborator

NCT02903615Not ApplicableCompleted

Optimising Health in Type 1 Diabetes

Role: lead

NCT04354818Unknown

Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)

Role: collaborator

NCT00551343Not ApplicableCompleted

Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

Role: lead

NCT02017210Completed

Insulin-sensitive Obesity: Lessons From Longitudinal Data

Role: lead

NCT00673894Not ApplicableCompleted

Effects of Glutamine on GLP-1 and Insulin Secretion in Man

Role: lead

NCT02501343Not ApplicableCompleted

Alkaline Diet for Insulin Sensitivity

Role: lead

NCT00592735Completed

Effects of Medical and Surgical Weight Loss on Metabolism

Role: lead

NCT00707603Completed

Chronic Hepatitis C and Insulin Resistance

Role: lead

NCT00562393Not ApplicableCompleted

Effects of Excess Energy Intake on Metabolic Risk

Role: lead

NCT00192621Phase 4Completed

Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects

Role: collaborator

NCT00227500Phase 4Completed

Pravastatin for Hyperlipidaemia in HIV.

Role: collaborator

All 15 trials loaded